Effect of Insulin Catheter Wear-Time on Subcutaneous Adipose Tissue Blood Flow and Insulin Absorption in Humans

被引:25
作者
Clausen, Trine Schnedler [1 ,2 ]
Kaastrup, Peter [2 ]
Stallknecht, Bente [1 ]
机构
[1] Univ Copenhagen, Dept Biomed Sci, Copenhagen, Denmark
[2] Novo Nordisk AS, Device Res & Technol, Hillerod, Denmark
关键词
INFUSION SITE; DIABETIC-PATIENTS; EFFICACY; FOREARM; ANALOG; CSII;
D O I
10.1089/dia.2009.0058
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Insertion of an insulin catheter for continuous subcutaneous insulin infusion into the subcutaneous adipose tissue (SAT) causes a tissue trauma that may have consequences for insulin absorption. We evaluated the importance of insulin catheter wear-time on subcutaneous adipose tissue blood flow (ATBF) and absorption of the rapid-acting insulin analog insulin aspart over a period of 4 days. Methods: Teflon insulin catheters (Medtronic, Minneapolis, MN) were inserted into the abdominal SAT of 10 healthy men without diabetes (mean +/- SEM age, 23.0 +/- 1.1 years; body mass index, 22.1 +/- 0.7 kg/m(2)) and connected to an insulin pump delivering a constant rate of isotonic saline for 4 days. Subjects participated in four study days ( days 0, 1, 2, and 4) during which ATBF around the catheter tip was measured by Xe-133 clearance and absorption of an insulin aspart bolus (0.1 U/kg) was measured for 4 h. Results: ATBF increased from day 0 to day 2 after catheter insertion (2.6 +/- 0.6 to 4.5 +/- 0.8 mL/100 g/min; P = 0.030). By day 4, ATBF had returned to day 0 level. Time to peak plasma insulin aspart concentration after bolus administration decreased with catheter wear-time from 55 +/- 3 min on day 0 to 45 +/- 4 min on day 4 (P = 0.019). Neither peak plasma concentration nor area under the curve of insulin aspart changed significantly. Conclusions: Insertion of a Teflon insulin catheter into the SAT results in increased ATBF and faster absorption of insulin aspart in a period of 4 days without any change in the total amount of insulin aspart absorbed.
引用
收藏
页码:575 / 580
页数:6
相关论文
共 35 条
[1]   A new insulin immunoassay specific for the rapid-acting insulin analog, insulin aspart, suitable for bioavailability, bioequivalence, and pharmacokinetic studies [J].
Andersen, L ;
Jorgensen, PN ;
Jensen, LB ;
Walsh, D .
CLINICAL BIOCHEMISTRY, 2000, 33 (08) :627-633
[2]   Subcutaneous adipose tissue blood flow varies between superior and inferior levels of the anterior abdominal wall [J].
Ardilouze, JL ;
Karpe, F ;
Currie, JM ;
Frayn, KN ;
Fielding, BA .
INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 (02) :228-233
[3]   Nitric oxide and β-adrenergic stimulation are major regulators of preprandial and postprandial subcutaneous adipose tissue blood flow in humans [J].
Ardilouze, JL ;
Fielding, BA ;
Currie, JM ;
Frayn, KN ;
Karpe, F .
CIRCULATION, 2004, 109 (01) :47-52
[4]   Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life [J].
Bruttomesso, D ;
Pianta, A ;
Crazzolara, D ;
Scaldaferri, E ;
Lora, L ;
Guarneri, G ;
Mongillo, A ;
Gennaro, R ;
Miola, M ;
Moretti, M ;
Confortin, L ;
Beltramello, GP ;
Pais, M ;
Baritussio, A ;
Casiglia, E ;
Tiengo, A .
DIABETIC MEDICINE, 2002, 19 (08) :628-634
[5]   BLOOD-FLOW IN SKIN, SUBCUTANEOUS ADIPOSE-TISSUE AND SKELETAL-MUSCLE IN THE FOREARM OF NORMAL MAN DURING AN ORAL GLUCOSE-LOAD [J].
BULOW, J ;
ASTRUP, A ;
CHRISTENSEN, NJ ;
KASTRUP, J .
ACTA PHYSIOLOGICA SCANDINAVICA, 1987, 130 (04) :657-661
[6]  
CLAUSEN TS, 2009, J PHARM TOXICOL 0326
[7]  
Haardt MJ, 1997, DIABETIC MED, V14, P407, DOI 10.1002/(SICI)1096-9136(199705)14:5<407::AID-DIA375>3.3.CO
[8]  
2-N
[9]   Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment -: A randomized study [J].
Hanaire-Broutin, H ;
Melki, V ;
Bessières-Lacombe, S ;
Tauber, JP .
DIABETES CARE, 2000, 23 (09) :1232-1235
[10]   SIDE-EFFECTS AND INDWELLING TIMES OF SUBCUTANEOUS CATHETERS FOR INSULIN INJECTIONS - A NEW DEVICE FOR INJECTING INSULIN WITH A MINIMUM OF PAIN IN THE TREATMENT OF INSULIN-DEPENDENT DIABETES-MELLITUS [J].
HANAS, R ;
LUDVIGSSON, J .
DIABETES RESEARCH AND CLINICAL PRACTICE, 1990, 10 (01) :73-83